Issue: 2010 > July/August > review

Novel therapies for hypereosinophilic syndromes

S.A. Antoniu


Background: Conventional therapies (corticosteroids,
cytotoxic agents or interferon-a) or newer compounds such imatinib are used specifically in subsets of hypereosinophilic syndromes (HES). However other therapies are still needed in this condition.
Objective: To review the novel therapies for HES discussing their advantages and shortcomings. Methods and Results: Preclinical and clinical data on novel tyrosine kinase inhibitors, anti-IL -5 antibodies or anti-CD52 antibodies (alemtuzumab) are analysed. The former might represent appropriate options in case of imatinib resistance; the efficacy of anti-IL-5 monoclonal antibodies therapy is limited by the occurrence of rebound eosinophilia and alemtuzumab might be a promising anti-eosinophil therapy for all HES subsets.
Conclusion: Some of the novel therapies might become
appropriate therapeutic options for HES .